Tomas Radivoyevitch

TL;DR: Significantly enriched in high-risk MDS, TP53, GATA2, KRAS, RUNX1, STAG2, ASXL1, ZRSR2 and TET2 mutations (type 2) had a weaker impact on sAML progression and overall survival than type-1 mutations.

TL;DR: The risk of S-N EC, but not A-NEC after GKSRS for non-AVM tumors correlates with 12-GyV, and increases significantly for 12- GyV>0 cc, while Radiosurgical plan conformality did not correlate with the development of S.NEC.

TL;DR: Cohesin mutations were significantly associated with RUNX1, Ras-family oncogenes, and BCOR and ASXL1 mutations and were most prevalent in high-risk MDS and secondary AML and were associated with poor overall survival.

TL;DR: Understanding of the biochemical consequences of IDH1/2 mutations in oncogenesis and survival prolongation will yield valuable information for rational therapy design: it will tell us which oncogenic processes should be blocked and which "survivalogenic" effects should be retained.

TL;DR: There was a temporal relationship with theCA4P infusion and with ECG changes consistent with an acute coronary syndrome in two patients, and it is advisable that future trials with CA4P have eligibility guidelines limiting patients with known coronary artery disease or those with multiple coronary arteries disease risk factors until more experience is gained regarding potential cardiovascular toxicity with this agent.